Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

BACKGROUND: RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall surv...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Boxerman, Jerrold L., Zhang, Zheng, Safriel, Yair, Larvie, Mykol, Snyder, Bradley S., Jain, Rajan, Chi, T. Linda, Sorensen, A. Gregory, Gilbert, Mark R., Barboriak, Daniel P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2013
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3688018/
https://ncbi.nlm.nih.gov/pubmed/23788270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not049
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi